00:00
00:00
00:00
ValiRx - US Patent Grant for VAL201

ValiRx Plc, the clinical stage biotechnology company, is pleased to provide an update following the notification of the US patent grant allowance for the therapeutic compound, VAL201. The compound is currently in a Phase I/II study primarily assessing safety and tolerability of VAL201 and its effect in the treatment of prostate cancer and other solid tumours.

Dr George Morris
Chief Operating Officer

Company Events - VALIRX PLC